These combined observations raise the possibility that DYRK1A may be a critical contributor to tau dysfunction and tau pathology of Alzheimer's disease and, moreover, that this kinase may be an important therapeutic target for pharmacological interventions seeking to modify the course of tau pathology in AD. This evidence concerns the gene MAPT and Alzheimer disease.